<p>法國巴黎銀行金融市場在最近向證券交易委員會（SEC）提交的 13F 表格中披露，在第四季度將其在 Travere Therapeutics, Inc.（NASDAQ:TVTX - 免費報告）的持股比例提高了 17.7%。該機構投資者在此期間額外購買了 100,198 股後，持有該公司 665,795 股股票。到最近一個季度末，法國巴黎銀行金融市場持有的 Travere Therapeutics 股份佔 0.74%，價值為 25,440,000 美元。</p>
<p>獲取 <strong>Travere Therapeutics</strong> 的提醒：</p>
<ul>
<li>3 家不為人知的醫療公司</li>
</ul>
<p>其他對沖基金最近也增加或減少了在該公司的持股。Raymond James Financial Inc. 在第二季度新購入了價值 33,000 美元的 Travere Therapeutics 股份。Torren Management LLC 在第四季度新購入了價值 38,000 美元的 Travere Therapeutics 股份。Comerica Bank 在第四季度將其在 Travere Therapeutics 的持股提高了 77.5%。Comerica Bank 現在持有該公司 1,127 股股票，價值 43,000 美元，此前在此期間又購買了 492 股。Garner Asset Management Corp 在第四季度新購入了價值 69,000 美元的 Travere Therapeutics 股份。最後，Headlands Technologies LLC 在第二季度新購入了價值 73,000 美元的 Travere Therapeutics 股份。</p>
<h2>Travere Therapeutics 的內部交易</h2>
<p>在其他消息中，首席會計官 Sandra Calvin 於 4 月 14 日（星期二）出售了 21,977 股該公司的股票。股票以平均價格 41.07 美元出售，總價值為 902,595.39 美元。出售完成後，首席會計官直接持有 42,353 股該公司的股票，估值約為 1,739,437.71 美元。此次交易代表其持股減少了 34.16%。該交易已在向 SEC 提交的文件中披露，文件可通過 SEC 網站訪問。該交易是在預先安排的 10b5-1 交易計劃下執行的。此外，董事 Roy D. Baynes 於 4 月 14 日（星期二）出售了 32,750 股該公司的股票。股票以平均價格 41.29 美元出售，總交易額為 1,352,247.50 美元。出售後，該董事直接持有 37,500 股公司股票，估值為 1,548,375 美元。此次交易代表其持股減少了 46.62%。該出售的披露信息可在 SEC 的文件中找到。該交易是在預先安排的 10b5-1 交易計劃下執行的。在過去的九十天裏，內部人士已出售了價值 15,895,428 美元的 400,015 股公司股票。公司內部人士持有公司股票的 4.44%。</p>
<h2>華爾街分析師預測增長</h2>
<ul>
<li>Travere Therapeutics 在鼓舞人心的數據後仍在上升</li>
</ul>
<p>TVTX 最近成為幾份分析師報告的主題。HC Wainwright 在週二的報告中將 Travere Therapeutics 的目標價格從 57.00 美元上調至 67.00 美元，並給予該公司 “買入” 評級。Guggenheim 在 4 月 24 日（星期五）的報告中將 Travere Therapeutics 的目標價格從 54.00 美元上調至 56.00 美元，並給予該公司 “買入” 評級。Wedbush 在週三重申了 “跑贏大盤” 評級，並對 Travere Therapeutics 的股票設定了 55.00 美元的目標價格。Wall Street Zen 在 5 月 9 日（星期六）的報告中將 Travere Therapeutics 的評級從 “買入” 下調至 “持有”。最後，花旗集團在週三將 Travere Therapeutics 的目標價格從 59.00 美元上調至 62.00 美元，並給予該公司 “買入” 評級。十位分析師對該股票給予了買入評級，兩位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Travere Therapeutics 目前的共識評級為 “適度買入”，共識目標價格為 48.92 美元。</p>
<p><strong>查看我們最新的 Travere Therapeutics 股票報告</strong></p>
<h2>Travere Therapeutics 股票上漲 2.2%</h2>
<p>週五，TVTX 股票開盤價為 46.18 美元。Travere Therapeutics, Inc.的 52 周低點為 13.88 美元，52 周高點為 48.61 美元。該公司的債務與股本比率為 3.16，速動比率為 3.08，流動比率為 3.13。該公司的 50 日簡單移動平均為 39.35 美元，200 日簡單移動平均為 34.71 美元。該公司的市值為 42.9 億美元，市盈率為-200.77，貝塔值為 1.13。</p>
<p>Travere Therapeutics（NASDAQ:TVTX - 獲取免費報告）最近於 5 月 4 日（星期一）發佈了其財報。該公司報告本季度每股收益為 0.05 美元，超出分析師共識預期的-0.24 美元，超出幅度為 0.29 美元。Travere Therapeutics 的淨利潤率為-4.00%，股本回報率為-26.16%。該公司在本季度的收入為 1.272 億美元，而共識預期為 1.3623 億美元。在去年同期，該公司每股收益為-0.47 美元。與去年同期相比，該公司的收入增長了 55.6%。研究分析師預計 Travere Therapeutics, Inc.將在本財年發佈-0.26 美元的每股收益。</p>
<h2>Travere Therapeutics 公司簡介</h2>
<p>（免費報告）</p>
<p>Travere Therapeutics, Inc.（NASDAQ: TVTX）是一家總部位於加利福尼亞州聖地亞哥的生物製藥公司，致力於開發和商業化針對罕見腎臟和遺傳疾病的療法。公司的使命是通過關注影響小患者羣體的疾病，解決治療選擇有限的疾病的未滿足需求。Travere 結合了研究、開發和商業能力，將創新藥物推向市場。</p>
<p>該公司的主要產品是 sparsentan，一種雙重內皮素 - 血管緊張素受體拮抗劑，已獲得美國的加速批准。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Travere Therapeutics</li>
<li>大規模 AI 服務器輪換使惠普企業和超微計算機成為焦點</li>
<li>Generac 的 AI 動力轉型引發了關於數據中心需求的更大問題</li>
<li>美敦力觸底，健康反彈在前</li>
<li>GitLab 的價格恢復獲得 traction——是時候上車了嗎？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Travere Therapeutics 嗎？</h2>
<p>在考慮 Travere Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前... 而 Travere Therapeutics 並不在名單上。</p>
<p>雖然 Travere Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

TVTX

<p>法國外貿銀行金融市場在第四季度將其在 Travere Therapeutics 的股份增加了 17.7%，達到 2544 萬美元。其他機構如 Comerica Bank 也增加了持股，而內部人士則根據 10b5-1 規則出售了股份。儘管最近的收益超出預期，分析師們普遍維持 “適度買入” 的共識，平均目標價格為 48.92 美元</p>

<p>BNP Paribas Financial Markets raised its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 17.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 665,795 shares of the company's stock after buying an additional 100,198 shares during the period. BNP Paribas Financial Markets owned 0.74% of Travere Therapeutics worth $25,440,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>法國巴黎銀行金融市場在最近向證券交易委員會（SEC）提交的 13F 表格中披露，在第四季度將其在 Travere Therapeutics, Inc.（NASDAQ:TVTX - 免費報告）的持股比例提高了 17.7%。該機構投資者在此期間額外購買了 100,198 股後，持有該公司 665,795 股股票。到最近一個季度末，法國巴黎銀行金融市場持有的 Travere Therapeutics 股份佔 0.74%，價值為 25,440,000 美元。</p>
</div><p>Get <strong>Travere Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Travere Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>3 Under-the-Radar Healthcare Companies</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家不為人知的醫療公司</li>
</ul>
</div><p>Other hedge funds have also recently added to or reduced their stakes in the company. Raymond James Financial Inc. acquired a new position in shares of Travere Therapeutics during the second quarter worth $33,000. Torren Management LLC acquired a new position in shares of Travere Therapeutics during the fourth quarter worth $38,000. Comerica Bank lifted its holdings in shares of Travere Therapeutics by 77.5% during the fourth quarter. Comerica Bank now owns 1,127 shares of the company's stock worth $43,000 after purchasing an additional 492 shares during the period. Garner Asset Management Corp acquired a new position in shares of Travere Therapeutics during the fourth quarter worth $69,000. Finally, Headlands Technologies LLC acquired a new position in shares of Travere Therapeutics during the second quarter worth $73,000.</p>
<div class="lb-trans"><p>其他對沖基金最近也增加或減少了在該公司的持股。Raymond James Financial Inc. 在第二季度新購入了價值 33,000 美元的 Travere Therapeutics 股份。Torren Management LLC 在第四季度新購入了價值 38,000 美元的 Travere Therapeutics 股份。Comerica Bank 在第四季度將其在 Travere Therapeutics 的持股提高了 77.5%。Comerica Bank 現在持有該公司 1,127 股股票，價值 43,000 美元，此前在此期間又購買了 492 股。Garner Asset Management Corp 在第四季度新購入了價值 69,000 美元的 Travere Therapeutics 股份。最後，Headlands Technologies LLC 在第二季度新購入了價值 73,000 美元的 Travere Therapeutics 股份。</p>
</div><h2>Insider Transactions at Travere Therapeutics</h2>
<div class="lb-trans"><h2>Travere Therapeutics 的內部交易</h2>
</div><p>In other news, CAO Sandra Calvin sold 21,977 shares of the firm's stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $41.07, for a total value of $902,595.39. Following the completion of the sale, the chief accounting officer directly owned 42,353 shares of the company's stock, valued at approximately $1,739,437.71. This trade represents a 34.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Roy D. Baynes sold 32,750 shares of the business's stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $41.29, for a total transaction of $1,352,247.50. Following the sale, the director directly owned 37,500 shares in the company, valued at $1,548,375. The trade was a 46.62% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 400,015 shares of company stock worth $15,895,428. Company insiders own 4.44% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，首席會計官 Sandra Calvin 於 4 月 14 日（星期二）出售了 21,977 股該公司的股票。股票以平均價格 41.07 美元出售，總價值為 902,595.39 美元。出售完成後，首席會計官直接持有 42,353 股該公司的股票，估值約為 1,739,437.71 美元。此次交易代表其持股減少了 34.16%。該交易已在向 SEC 提交的文件中披露，文件可通過 SEC 網站訪問。該交易是在預先安排的 10b5-1 交易計劃下執行的。此外，董事 Roy D. Baynes 於 4 月 14 日（星期二）出售了 32,750 股該公司的股票。股票以平均價格 41.29 美元出售，總交易額為 1,352,247.50 美元。出售後，該董事直接持有 37,500 股公司股票，估值為 1,548,375 美元。此次交易代表其持股減少了 46.62%。該出售的披露信息可在 SEC 的文件中找到。該交易是在預先安排的 10b5-1 交易計劃下執行的。在過去的九十天裏，內部人士已出售了價值 15,895,428 美元的 400,015 股公司股票。公司內部人士持有公司股票的 4.44%。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><ul>
<li>Travere Therapeutics Still On The Rise After Encouraging Data</li>
</ul>
<div class="lb-trans"><ul>
<li>Travere Therapeutics 在鼓舞人心的數據後仍在上升</li>
</ul>
</div><p>TVTX has been the topic of several recent analyst reports. HC Wainwright boosted their target price on shares of Travere Therapeutics from $57.00 to $67.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday. Guggenheim boosted their target price on shares of Travere Therapeutics from $54.00 to $56.00 and gave the company a &#34;buy&#34; rating in a report on Friday, April 24th. Wedbush restated an &#34;outperform&#34; rating and issued a $55.00 target price on shares of Travere Therapeutics in a report on Wednesday. Wall Street Zen lowered shares of Travere Therapeutics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday, May 9th. Finally, Citigroup boosted their target price on shares of Travere Therapeutics from $59.00 to $62.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Travere Therapeutics presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $48.92.</p>
<div class="lb-trans"><p>TVTX 最近成為幾份分析師報告的主題。HC Wainwright 在週二的報告中將 Travere Therapeutics 的目標價格從 57.00 美元上調至 67.00 美元，並給予該公司 “買入” 評級。Guggenheim 在 4 月 24 日（星期五）的報告中將 Travere Therapeutics 的目標價格從 54.00 美元上調至 56.00 美元，並給予該公司 “買入” 評級。Wedbush 在週三重申了 “跑贏大盤” 評級，並對 Travere Therapeutics 的股票設定了 55.00 美元的目標價格。Wall Street Zen 在 5 月 9 日（星期六）的報告中將 Travere Therapeutics 的評級從 “買入” 下調至 “持有”。最後，花旗集團在週三將 Travere Therapeutics 的目標價格從 59.00 美元上調至 62.00 美元，並給予該公司 “買入” 評級。十位分析師對該股票給予了買入評級，兩位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Travere Therapeutics 目前的共識評級為 “適度買入”，共識目標價格為 48.92 美元。</p>
</div><p><strong>View Our Latest Stock Report on Travere Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 Travere Therapeutics 股票報告</strong></p>
</div><h2>Travere Therapeutics Trading Up 2.2%</h2>
<div class="lb-trans"><h2>Travere Therapeutics 股票上漲 2.2%</h2>
</div><p>Shares of TVTX stock opened at $46.18 on Friday. Travere Therapeutics, Inc. has a 52-week low of $13.88 and a 52-week high of $48.61. The company has a debt-to-equity ratio of 3.16, a quick ratio of 3.08 and a current ratio of 3.13. The company has a 50-day simple moving average of $39.35 and a two-hundred day simple moving average of $34.71. The company has a market capitalization of $4.29 billion, a price-to-earnings ratio of -200.77 and a beta of 1.13.</p>
<div class="lb-trans"><p>週五，TVTX 股票開盤價為 46.18 美元。Travere Therapeutics, Inc.的 52 周低點為 13.88 美元，52 周高點為 48.61 美元。該公司的債務與股本比率為 3.16，速動比率為 3.08，流動比率為 3.13。該公司的 50 日簡單移動平均為 39.35 美元，200 日簡單移動平均為 34.71 美元。該公司的市值為 42.9 億美元，市盈率為-200.77，貝塔值為 1.13。</p>
</div><p>Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its earnings results on Monday, May 4th. The company reported $0.05 earnings per share for the quarter, beating analysts' consensus estimates of ($0.24) by $0.29. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 26.16%. The firm had revenue of $127.20 million during the quarter, compared to the consensus estimate of $136.23 million. During the same period in the prior year, the firm earned ($0.47) EPS. The company's revenue was up 55.6% compared to the same quarter last year. Research analysts anticipate that Travere Therapeutics, Inc. will post -0.26 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Travere Therapeutics（NASDAQ:TVTX - 獲取免費報告）最近於 5 月 4 日（星期一）發佈了其財報。該公司報告本季度每股收益為 0.05 美元，超出分析師共識預期的-0.24 美元，超出幅度為 0.29 美元。Travere Therapeutics 的淨利潤率為-4.00%，股本回報率為-26.16%。該公司在本季度的收入為 1.272 億美元，而共識預期為 1.3623 億美元。在去年同期，該公司每股收益為-0.47 美元。與去年同期相比，該公司的收入增長了 55.6%。研究分析師預計 Travere Therapeutics, Inc.將在本財年發佈-0.26 美元的每股收益。</p>
</div><h2>Travere Therapeutics Profile</h2>
<div class="lb-trans"><h2>Travere Therapeutics 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Travere Therapeutics, Inc NASDAQ: TVTX is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.</p>
<div class="lb-trans"><p>Travere Therapeutics, Inc.（NASDAQ: TVTX）是一家總部位於加利福尼亞州聖地亞哥的生物製藥公司，致力於開發和商業化針對罕見腎臟和遺傳疾病的療法。公司的使命是通過關注影響小患者羣體的疾病，解決治療選擇有限的疾病的未滿足需求。Travere 結合了研究、開發和商業能力，將創新藥物推向市場。</p>
</div><p>The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.</p>
<div class="lb-trans"><p>該公司的主要產品是 sparsentan，一種雙重內皮素 - 血管緊張素受體拮抗劑，已獲得美國的加速批准。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Travere Therapeutics</li>
<li>The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in Focus</li>
<li>Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand</li>
<li>Medtronic Bottoms, Healthy Rebound Ahead</li>
<li>GitLab’s Price Recovery Gains Traction—Time to Get On Board?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Travere Therapeutics</li>
<li>大規模 AI 服務器輪換使惠普企業和超微計算機成為焦點</li>
<li>Generac 的 AI 動力轉型引發了關於數據中心需求的更大問題</li>
<li>美敦力觸底，健康反彈在前</li>
<li>GitLab 的價格恢復獲得 traction——是時候上車了嗎？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=TVTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Travere Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Travere Therapeutics 嗎？</h2>
</div><p>Before you consider Travere Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Travere Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Travere Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前... 而 Travere Therapeutics 並不在名單上。</p>
</div><p>While Travere Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Travere Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

BNP Paribas Financial Markets Has $25.44 Million Stock Position in Travere Therapeutics, Inc. $TVTX

Market Beat

Travere Therapeutics

法國巴黎銀行(ADR)

瑞傑金融

Comerica

花旗

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

COMERICA INC 6.875 % DEP PFD SER B

CITIGROUP INC 6.250 NON CUM SER II PFD WI

法國巴黎銀行金融市場在 Travere Therapeutics, Inc. $TVTX 持有價值 2544 萬美元的股票頭寸